Portfolio news

Engimmune Therapeutics is a platform and product development company using cutting-edge technologies in the life sciences to engineer highly potent and specific therapies based on…

We are proud to announce the recent expansion of our portfolio of companies. We welcome two newcomers - Incephalo and NextImmune - to our family.…

Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…

Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…

We are very proud to announce that Synendos Therapeutics has raised a USD 21M series A co-led by Kurma Partners and Sunstone Life Science Ventures.…